ResMed Inc. (NYSE:RMD - Free Report) - Equities researchers at Zacks Research raised their Q1 2026 earnings per share estimates for shares of ResMed in a research note issued on Thursday, May 22nd. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.37 per share for the quarter, up from their previous forecast of $2.36. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q2 2026 earnings at $2.48 EPS, Q3 2026 earnings at $2.51 EPS, FY2026 earnings at $9.83 EPS and FY2027 earnings at $10.71 EPS.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The firm's revenue was up 7.9% on a year-over-year basis.
RMD has been the topic of several other reports. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. JPMorgan Chase & Co. boosted their target price on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Piper Sandler lowered their price target on ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a research note on Thursday, April 24th. Finally, Mizuho set a $265.00 price target on ResMed in a research note on Wednesday, April 16th. One analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ResMed currently has a consensus rating of "Moderate Buy" and an average target price of $259.33.
Read Our Latest Research Report on ResMed
ResMed Stock Up 1.4%
RMD traded up $3.42 on Monday, reaching $246.26. 1,056,206 shares of the company traded hands, compared to its average volume of 1,023,598. The stock's 50 day moving average price is $228.30 and its 200-day moving average price is $234.10. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed has a 52-week low of $179.42 and a 52-week high of $263.05. The company has a market cap of $36.11 billion, a price-to-earnings ratio of 29.07, a PEG ratio of 1.53 and a beta of 0.78.
ResMed Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's dividend payout ratio (DPR) is currently 23.79%.
Insider Transactions at ResMed
In other news, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the sale, the insider now owns 9,725 shares of the company's stock, valued at approximately $2,289,265. This trade represents a 48.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total transaction of $455,420.00. Following the sale, the director now owns 75,218 shares in the company, valued at $17,127,890.78. This represents a 2.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,949 shares of company stock worth $11,822,260. Insiders own 0.71% of the company's stock.
Institutional Investors Weigh In On ResMed
A number of institutional investors have recently bought and sold shares of RMD. First Horizon Advisors Inc. boosted its position in shares of ResMed by 285.1% during the 4th quarter. First Horizon Advisors Inc. now owns 593 shares of the medical equipment provider's stock valued at $136,000 after acquiring an additional 439 shares in the last quarter. Spire Wealth Management boosted its holdings in ResMed by 11.3% during the fourth quarter. Spire Wealth Management now owns 10,800 shares of the medical equipment provider's stock valued at $2,470,000 after purchasing an additional 1,100 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in ResMed by 2.8% during the fourth quarter. Asset Management One Co. Ltd. now owns 60,489 shares of the medical equipment provider's stock valued at $14,105,000 after purchasing an additional 1,629 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in ResMed by 38.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,830 shares of the medical equipment provider's stock valued at $2,989,000 after purchasing an additional 3,576 shares in the last quarter. Finally, Cumberland Partners Ltd boosted its stake in ResMed by 550.0% in the 4th quarter. Cumberland Partners Ltd now owns 13,000 shares of the medical equipment provider's stock valued at $2,973,000 after buying an additional 11,000 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.
ResMed Company Profile
(
Get Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Further Reading
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
